Comparison of the Safety and Efficacy of Warfarin Versus Rivaroxaban in Northern Chinese Patients with Different CHA2DS2-VASc Scores: A Retrospective Cohort Study  

作　　者：Shiwei Xu Qi Zhao Haiyu Zhang Xianghui Li Jing Lu Hongyan Wang Yuanyuan Guo Zengxiang Dong 

机构地区：[1]Department of Pharmacy,the Second Affiliated Hospital of Harbin Medical University,148 Baojian Road,Nangang District,Harbin,150001,China [2]Department of Pharmacy,the First Affiliated Hospital of Harbin Medical University,23 Youzheng Street,Nangang District,Harbin,150001,China [3]The Key Laboratory of Cardiovascular Disease Acousto-Optic Electromagnetic Diagnosis and Treatment in Heilongjiang Province,the First Affiliated Hospital of Harbin Medical University,23 Youzheng Street,Nangang District,Harbin 150001,China [4]Department of Geriatrics,the First Affiliated Hospital of Harbin Medical University,23 Youzheng Street,Nangang District,Harbin,150001,China [5]NHC Key Laboratory of Cell Transplantation,the First Affiliated Hospital of Harbin Medical University,23 Youzheng Street,Nangang District,Harbin,150001,China

出　　处：《Cardiovascular Innovations and Applications》2023年第1期203-212,共10页心血管创新与应用(英文)

基　　金：The study was funded by the National Natural Science Foundation of China(No.81900366);the Postdoctoral Initiation Foundation of Heilongjiang Province(LBH-Q19032);the Research Project of the First Affiliated Hospital of Harbin Medical University(2021J01).

摘　　要：Purpose:This study was aimed at evaluating the safety and efficacy of warfarin versus rivaroxaban in patients with atrial fibrillation(AF)and different CHA2DS2-VASc score subgroups in northern China.Methods:A retrospective cohort study was conducted to evaluate 387 patients with AF who received treatment at our institution between September 2018 and August 2019.The patients were divided into two groups receiving either warfarin(n=194)or rivaroxaban(n=193).Follow-up data were collected,including adherence,bleeding and ischemic stroke events.Results:The group receiving rivaroxaban showed better adherence than the group receiving warfarin.In the warfarin-treated group,bleeding incidents declined with increasing scores.In the warfarin-treated group,patients with scores of 2–3 had greater adherence and fewer stroke occurrences.The events of bleeding and stroke did not significantly differ in patients in the rivaroxaban-treated group with different scores.Conclusions:Compared with patients in the warfarin group with different CHA2DS2-VASc scores,those in the rivaroxaban group had greater compliance,and fewer bleeding and stroke events.Regardless of economic considera-tions,rivaroxaban is preferable for anticoagulative AF treatment in northern Chinese patients.

关 键 词：Atrial fibrillation WARFARIN RIVAROXABAN Ischemic stroke CHA2DS2-VASc score 

分 类 号：R541.7[医药卫生—心血管疾病]